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Abstract
Purpose With the availability of ultra-sensitive PSA assays, early biochemical relapse (eBCR) of prostate cancer is increasingly
being detected at values much lower than the conventional threshold of 0.2 ng/ml. Accurate localisation of disease in this setting
may allow treatment modification and improved outcomes, especially in patients with pelvis-confined or extra-pelvic
oligometastasis (defined as up to three pelvic nodal or distant sites). We aimed to measure the detection rate of [68]Ga-
PSMA-HBNED-CC (PSMA)-PET/CT and its influence on patient management in eBCR of prostate cancer following radical
prostatectomy (RP).
Methods We retrospectively identified 28 patients who underwent PSMA-PET/CT for post-RP eBCR (PSA < 0.5 ng/ml) at our
tertiary care cancer centre. Two nuclear medicine physicians independently recorded the sites of PSMA-PET/CT positivity.
Multidisciplinary meeting records were accessed to determine changes in management decisions following PSMA-PET/CT scans.
Results The mean age of patients was 65.6 years (range: 50–76.2 years); median PSA was 0.22 ng/ml (interquartile range:
0.15 ng/ml to 0.34 ng/ml). Thirteen patients (46.4%) had received radiotherapy in the past. PSMA-PET/CT was positive in 17
patients (60.7%). Only one patient had polymetastasis (> 3 sites); the remainder either had prostatectomy bed recurrence (n = 2),
pelvic oligometastasis (n = 10), or extra-pelvic oligometastasis (n = 4). PSMA-PET/CT resulted in management change in 12
patients (42.8%), involving stereotactic body radiotherapy (n = 6), salvage radiotherapy (n = 4), and systemic treatment (n = 2).
Conclusions Our findings show that PSMA-PET/CT has a high detection rate in the eBCR setting following RP, with a large
proportion of patients found to have fewer than three lesions. PSMA-PET/CT may be of value in patients with early PSA failure,
and impact on the choice of potentially curative salvage treatments.
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Introduction
Despite advances in surgical technique, post-prostatectomy
biochemical relapse (BCR) remains a significant problem,
with 20% to 30% patients experiencing prostate-specific anti-
gen (PSA) failure following radical prostatectomy (RP). A
proportion of these patients harbour a low disease burden
within the pelvis or extrapelvic oligometastases, especially
during the early stages of BCR [1, 2]. Numerous studies have
shown the advantage of early intervention in BCR when dis-
ease burden is low, and it has been shown that there is a loss of
2.6% biochemical control per 0.1 ng/ml rise in PSA [3]. For
patients undergoing PSA monitoring, a PSA threshold of
0.2 ng/ml has been proposed to offer prostate bed salvage
radiotherapy (SRT), with more recent evidence advocating
SRT even earlier — at first sign of detectable PSA — with
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improved long-term disease control [3–5]. Following empiri-
cal SRT for BCR, a proportion of patients still relapse due to
occult oligometastatic disease outside the prostate bed [6, 7].
Hence, more sensitive detectionmethods to localise individual
disease sites could allow personalised treatment in early BCR
(eBCR), defined here as PSA < 0.5 ng/ml.
Conventional imaging modalities used to detect prostate
cancer include CT, bone scan, MRI, and more recently, cho-
line-PET/CT. Although choline-PET/CT is widely considered
the most sensitive of these tests, they are all typically negative
at low PSA values, with most guidelines not recommending
any of these modalities at PSA < 2 ng/ml [8]. Recently, Ga-68
labeled (Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)]
prostate-specific membrane antigen (PSMA) PET/CT has
emerged as a more promising imaging modality in prostate
cancer detection. Compared with choline-PET/CT, lymphad-
enectomy series have quantified its sensitivity and specificity
as 65.9% and 98.9%, versus the reported sensitivity and spec-
ificity respectively of 49.2% and 95% for choline-PET/CT [8].
In one study, PSMA-PET/CT detected lesions in 44% patients
with negative choline-PET/CT scans [8].
The detection rate of Ga-68-PSMA-11 PET/CT and its
impact on patient management has been reported in a
number of studies. The majority of the previous studies
comprised heterogeneous patient populations including
patients undergoing baseline staging mixed with patients
with BCR in the post-RP and post-RT settings, over a
wide range of PSA levels [9–11]. Only limited data are
available on the impact of PSMA-PET/CT on the manage-
ment of post-RP eBCR [7, 12]. One study reported detec-
tion of extra-pelvic oligometastases in 12.2% of patients
in this setting [13]. Due to the potential benefit of targeted
treatment of oligometastatic relapse detected by the previ-
ous generation of imaging studies [14], estimation of the
efficicacy of PSMA-PET/CT in detecting oligometastases
will support the design of therapeutic trials aimed at mea-
suring long-term outcomes of these patients.
The primary objective of our study was to evaluate the
proportion of patients with post-RP eBCR who were diag-
nosed with oligometastatic recurrence outside the prostatecto-
my bed following Ga-68-PSMA-11 PET/CT; the secondary
objective was to document changes in patient management as
a result of Ga-68 PSMA-11 PET/CT examinations.
Materials and methods
Between 2015 and 2017, 152 patients underwent Ga-68
PSMA-11 PET/CT for BCR following radical prostatectomy,
and had recorded multidisciplinary team (MDT) management
plans. Patients were excluded if their PSAwas > 0.5 ng/ml. As
a result, 122 patients were excluded and the final cohort in-
cluded 28 patients, none of whom had recently received
abiraterone (i.e., within the past 12 months). If a patient had
undergone more than one PSMA-PET/CT scan, his first scan
was used for the study. The study proposal was approved by
the Committee for Clinical Research of the Royal Marsden
Hospital (SE705).
Image acquisition
Ga-68-labelled PSMA-11 was obtained commercially from
Mallinckrodt/Curium Pharma (London, UK). Patients were
injected intravenously with a median dose of 126 MBq Ga-
68 PSMA–11 (range 106–154 MBq) and, 60 minutes after
injection, were imaged from the base of the skull to midthighs
using a Gemini PET/CT scanner (Philips Medical Systems,
Cleveland, OH, USA). Data were acquired for 3.0 min per
bed position following low-dose CT scan (120 kV, 50mAs)
for attenuation correction. PET data sets were reconstructed
using ordered subset expectation maximization iterative re-
construction incorporating time-of-flight (three iterations and
33 subsets). Data were corrected for randoms, scatter, and
attenuation; matrix size was 144 × 144 (4 mm pixel spacing).
Lesion analysis
Ga-68-PSMA PET/CT scans were independently interpreted
on a Hermes hybrid viewer workstation (Hermes Medical
Solutions, Stockholm, Sweden) by two nuclear medicine phy-
sicians, in line with published guidelines [15]. Ga-68-PSMA
uptake was quantified in terms of SUVmax. Any focal uptake
greater than background not attributable to physiologic activ-
ity was considered positive for malignancy, and correlated
with low-dose CT for morphologic findings. In the literature,
oligometastatic disease has been defined variably in terms of
number and sites of lesions [1, 13, 16]. We defined
oligometastasis as ≤ 3 N1 or M1a lesions [17]. Lesion num-
bers and sites were recorded per patient as prostatectomy-bed
recurrence, pe lv ic o l igometas tas is , ext ra-pelvic
oligometastasis (without or in addition to pelvic lesions),
and polymetastasis (> 3 lesions).
MDT decision review
We retrospectively accessed patient records to review man-
agement decisions undertaken based on MDT discussion of
each case. At our institution, patients do not routinely undergo
pelvic lymph node dissection at the time of radical prostatec-
tomy. The standard of care of eBCR following radical prosta-
tectomy, in the absence evidence of disease outside the pros-
tatectomy bed, comprises prostatectomy bed radiotherapy.
The impact of PSMA-PET/CT on management was mea-
sured as the proportion of patients whose treatment was
changed from a previous plan. Management options were
categorised as PSA monitoring, androgen deprivation
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treatment (ADT; with or without chemotherapy), localised
treatment of oligometastases (surgery or sterotactic body ra-
diotherapy [SBRT]), and SRT.
Statistical analysis
For continuous variables, means and standard deviations are
reported. PSMA-PET positive and negative groups were com-
pared in terms of PSA levels using the Wilcoxon test, and in
terms of management decision using Fisher’s exact test. The
level of significance was set at 0.05. All statistical analysis
was done using R version 3.3.5 [18].
Results
We identified 28 patients with mean age 65.6 years (range 50–
76.2 years) and PSA median 0.22 ng/ml (interquartile range:
0.15–0.34). Six patients had receivedADT in the past (i.e., more
than 12 months before PSMA-PET imaging). Thirteen patients
had also received radiotherapy (prostatectomy bed only, n = 11;
prostatectomy bed plus pelvic lymph nodes, n = 2) adjuvantly
(n = 1) or as salvage treatment for a previous BCR (n = 12).
Clinical characteristics of the 28 patients are presented inTable 1.
PSMA-PET/CT was positive in 17 patients (60.7%) and
negative in 11 (39.3%). PSA values in the positive and nega-
tive categories were similar (mean 0.26 ± 0.14 and 0.23 ±
0.15, respectively; p = 0.57). Comparing PSMA-negative
and PSMA-positive groups, adopted treatment strategies were
significantly different (Fisher exact test; p < 0.0001). Figure 1
provides a graphical overview of sites of PSMA-PET positiv-
ity. Figure 2 illustrates site-wise breakdown of treatment
plans. In summary, all patients with PSMA-PET/CT positive
findings underwent treatment, whereas only three of 11 pa-
tients with negative scans were actively treated, the remainder
(n = 8) undergoing continued PSA monitoring with a plan to
repeat PSMA-PET after a short-term follow-up.
PSMA-PET/CT resulted in a change of management in 12
of 28 (42.8%) patients (red coloured bars in Fig. 2): There was
no change in management of patients with a negative PSMA-
PET/CT. Of the ten patients with pelvic oligometastases, four
patients received extended pelvic SRT (including pelvic
lymph nodes). The original plan in three of these patients
had been to irradiate the prostatectomy bed only, and in one
patient (PSA 0.1 ng/ml), to continue PSA monitoring. In three
patients with pelvic oligometastases, ADT was instituted and
PSMA-PET/CT did not change the treatment plan; all three
patients had received pelvic SRT due to a previous relapse,
and further pelvic irradiation could not be offered due to the
risk of toxicity. All four patients with extra-pelvic
oligometastases had a change in management plan based on
the detection of extra-pelvic disease. Whereas three patients
received site-specific treatment (surgery or SBRT), one patient
with extra-pelvic bone metastasis was not offered ablative
treatment and management was changed to ADT.
Past radiotherapy also seemed to have an impact on sites of
PSMA-PET positivity: Neither of the patients with prostatec-
tomy bed recurrence had a history of prostate bed radiothera-
py. Of the ten patients with pelvic oligometastasis, six patients
had received prostate bed only radiotherapy, and one patient
with a sacral bone metastasis had previously received prosta-
tectomy bed and pelvic lymph node radiotherapy. Hence,
none of the patients with prior history of radiotherapy had
in-field recurrence.
Follow-up of patients after PSMA-PET-directed
management
All patients with positive PSMA-PET/CT (n = 17) were given
either long-term palliative ADT or short-term ADT alongside
Table 1 Clinical and pathologic characteristics of the study population
(n = 28)
Clinical variable Value
Mean age (years) 65.6 (range 50–76.2)
PSA at time of assessment (ng/ml)a
Mean 0.24 (SD 0.12)
Median 0.22 (IQR 0.15–0.34)
PSA pre-prostatectomy (ng/ml)
Mean 11 (SD 9.07)
Median 7.6 (IQR 5.7–11.35)
Gleason score
6–7 21 (75%)
8–10 7 (25%)
Tumour stage
T2 7 (25%)
T3 21 (75%)
Nodal stage
N0 18 (64%)
N1 4 (14%)
Nx 6 (22%)
Positive margin
R0 14 (50%)
R1 8 (29%)
Unknown 6 (21%)
NCCN risk group
Intermediate 3 (11%)
High 23 (82%)
Unknown 2 (7%)
Previous androgen dDeprivation treatment b 6 (21.4%)
Previous radiotherapy
Prostatectomy bed only 11 (39.2%)
Prostatectomy bed and pelvic nodes 2 (7.1%)
a PSA-value at the time of referral for PSMA-PET/CT
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oligometastasis treatment. In all treated patients, PSA fell to
undetectable levels. However, two patients — both recipients
of PSMA-guided SBRT— experienced a further relapse within
6 months: one patient had a PSMA-avid lesion in the vas
deferens which was surgically excised, but subsequently re-
lapsed at the same site. Regarding the other patient, a PSMA-
positive common iliac lymph node was treated with SBRT and
ADT. After an initial drop, his PSA rose from 0.4 ng/ml at initial
PSMA-PET/CT to 1.17 ng/ml over the next 6 months, possibly
due to occult disease sites at the time of the initial PSMA-PET/
CTscan. However, subsequent imaging did not detect the site(s)
of relapse over 13 months of follow-up from the end of SBRT.
In all patients with a negative PSMA-PET/CT scan who
received treatment (SRT; n = 3), PSA became undetectable.
Of the patients with negative PSMA-PET/CT on PSA moni-
toring (n = 8), PSA became undetectable in one patient (PSA
at time of imaging 0.07 ng/ml) and continued to rise in seven
patients. In one of these patients with negative PSMA-PET/
CT (PSA at time of initial imaging 0.1 ng/ml), a third serial
Ga-68 PSMA–11 scan became positive when PSA rose to
0.4 ng/ml, showing a pathological pelvic lymph node
(Fig. 3). This patient was then given SRT. The remaining six
PSMA-PET/CT negative patients are still undergoing PSA
monitoring with a median follow-up period of 11 months
(range 5–17 months) at the time of writing.
Discussion
With few exceptions, the majority of studies reporting the
detection rates of PSMA-PET/CT in BCR involve heteroge-
neous patient cohorts including patients who have recently
received ADT before PSMA-PET, have undergone either RP
or RT, or have a wide range of PSAwith relatively few cases in
the eBCR category [9–11]. Conventional imaging may also
detect disease when the PSA levels are more elevated— being
associated with higher disease burden. The incremental bene-
fit of PSMA-PET/CT over conventional imaging remains to
be established at higher PSA values. Reviewing PSMA-PET/
Fig. 2 Flowchart illustrating sites of disease and management plans. Bars above the management plans show whether PSMA-PET/CT changed
management (red) or not (blue). eBCR = early biochemical recurrence. SRT = salvage radiotherapy. ADT = androgen deprivation treatment. Rx = therapy
Fig. 1 Site-wise distribution of individual lesions in 16 patients with
prostatectomy bed relapse or oligometastasis; the one patient with
polymetastasis is not included in this analysis. Green-shaded region
shows typical pelvic lymph node radiotherapy fields. The lymph node
short axes were median 5 mm (range 3 mm to 8 mm)
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CT detection rates in the eBCR sub-category of previous re-
ports, our detection rate of 57% falls within the published
range of 45% to 60% [7, 9, 10, 12, 19–22].
Our trend of disease-localisation is similar to that re-
ported in recent studies in the early BCR (PSA < 1 ng/ml)
setting in post-RP patients [12, 13]. For example, Calais
et al. reported pelvis-confined disease in 99 (36.7%),
extra-pelvic oligometastases in 33 (12.2%), and
polymetastases in six patients (2.2%) [13]. Their defini-
tion of oligometastases included extra-pelvic sites only. In
another study by Emmett et al. [12], the authors reported
pelvis-confined disease in 79 of 164 patients (48%) and
distant metastases in 23 (14%), the remainder (n = 62;
38%) being negative. The authors of this study did not
fur ther character ise disease burden in terms of
polymetastases and oligometastases; therefore, the fre-
quency of oligometastasis in their cohort cannot be
commented on. An important departure between our study
and both these studies is the much higher frequency of
prostatectomy bed recurrence of 17.5% and 23% reported
by Calais et al. and Emmet et al. respectively, compared
with only 7.1% (n = 2) in our study. We believe this dif-
ference is because 11 of our patients had received
prostatectomy-bed radiotherapy in the past, and a further
two had undergone prostatectomy-bed and lymph node
radiotherapy, which would have arguably lowered the risk
of future relapses at these sites. We suspect that the actual
proportion of prostatectomy-bed relapse is even higher
than tha t repor ted by these two groups , s ince
prostatectomy-bed activity is likely to be masked due to
the high urine concentration of PSMA in the bladder [23].
In a recent study on a homogeneous cohort (n = 119) of
patients with early post-RP BCR (PSA 0.2–0.5 ng/ml), Farolfi
et al. reported a detection rate of 34% [24]. Unlike some pa-
tients in our study, none in their cohort had received SRT in
the past. Nevertheless, the detection rate was much lower,
despite the absence of previous SRT which might have
sterilised the pelvic sites and lowered the probability of pelvic
recurrence. It is possible that since a proportion of their pa-
tients had received ADT (7.6% at the time of imaging and
23.5% during recurrence), PSMA expression was suppressed
in a number of cases, leading to a lower detection rate.
Regarding the negative results in 11 patients (39.3%),
we believe that PSMA-PET/CT should be considered
false negative in most cases, although a proportion of
patients may have low PSMA expressing disease. It
has been previously pointed out that despite its superior
sensitivity compared to other imaging modalities, detect-
ing a very low disease burden remains challenging for
PSMA-PET/CT, especially when lesions are < 4 mm, as
exemplified in Fig. 3 [15]. Although PSMA is over-
expressed in all prostate cancer cases, the intensity of
over-expression varies, and around 50% of tumours
show relatively low degrees of PSMA over-expression
and correspondingly lower SUVs on PSMA-PET/CT, ir-
respective of PSA levels [25–27]. The significance of a
negative PSMA-PET/CT has been highlighted recently
by Emmett et al., who showed high PSA-response rates
(85%) to SRT in patients with negative PSMA-PET/CT,
suggesting pelvis-confined disease in the majority of pa-
tients with a negative PSMA-PET/CT, especially within
the prostatectomy bed, which may be obscured due to
the very close proximity to high urinary PSMA activity
[12].
Our retrospective study has several limitations: 13 out of 28
patients in our relatively small cohort had received SRT
Fig. 3 Serial Ga-68-PSMA-PET/CT in a 67-year-old man with BCR
following radical prostatectomy and prostatectomy bed radiotherapy. a
Initial scan at PSA 0.1 ng/ml. Left internal iliac lymph node (arrow)
considered benign, morphologically (< 4 mm diameter) and
metabolically (SUV 1.2). b PSA rise to 0.2 ng/ml, follow-up scan after
4 months. Minimal enlargement of the lymph node, still within normal
limits (SUV 0.7; PSA). c Further PSA rise to 0.4 ng/ml, follow up scan
5 months after b. Lymph node remains subcentimetre (6 mm), but due to
high PSMA uptake (SUVmax 8.2), now considered suspicious for
malignant metastasis
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previously. This could have potentially skewed the detection
rates in favour of extra-pelvic sites. Secondly, we did not have
definitive pathologic proof of disease positivity in the majority
of our patients, who were all imaged in the course of routine
clinical assessment. Referrers proceeded with treatment based
on clinical judgement and reported specificity of PSMA; thus,
pathological confirmation was not obtained in most cases [8].
Obviously, PSA-response cannot be used to confirm the effi-
cacy of PSMA-PET/CT guided local treatment, since most of
our patients received ADT. Follow-up of our cohort continues
and long-term outcomes of patients with PSMA-PET/CT pos-
itive versus negative will be assessed at a later date.
Conclusion
Our study shows that PSMA-PET/CT has a clinically significant
rate of prostate cancer detection in post-RP patients with eBCR
despite very low PSA levels. PSMA PET/CT suggested limited
oligometastatic disease in half of the patients in our cohort. Given
the increasingly lower threshold for active treatment of BCR,
PSMA-PET/CTis uniquely advantageous in influencingmanage-
ment of these patients. However, whether this change in manage-
ment, i.e., PSMA-guided alteration in SRT fields or ablative treat-
ment of oligometatic sites, translates into improved long-term
outcome needs to be investigated in prospective studies.
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